Roth MKM Reiterates Buy on First Wave BioPharma, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Jonathan Aschoff has reiterated a 'Buy' rating on First Wave BioPharma (NASDAQ:FWBI) and maintained the price target at $11.
September 19, 2023 | 1:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roth MKM analyst has reiterated a 'Buy' rating on First Wave BioPharma and maintained the price target at $11.
The reiteration of a 'Buy' rating by a Roth MKM analyst and the maintenance of the price target at $11 indicates a positive outlook for First Wave BioPharma. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100